MX340714B - Inhibidores de hsp90. - Google Patents

Inhibidores de hsp90.

Info

Publication number
MX340714B
MX340714B MX2012004089A MX2012004089A MX340714B MX 340714 B MX340714 B MX 340714B MX 2012004089 A MX2012004089 A MX 2012004089A MX 2012004089 A MX2012004089 A MX 2012004089A MX 340714 B MX340714 B MX 340714B
Authority
MX
Mexico
Prior art keywords
purine derivatives
derivatives useful
hsp90 inhibitors
hsp90
inhibitors
Prior art date
Application number
MX2012004089A
Other languages
English (en)
Other versions
MX2012004089A (es
Inventor
Chiosis Gabriela
Taldone Tony
Sun Weilin
Original Assignee
Sloan-Kettering Inst For Cancer Res *
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sloan-Kettering Inst For Cancer Res * filed Critical Sloan-Kettering Inst For Cancer Res *
Publication of MX2012004089A publication Critical patent/MX2012004089A/es
Publication of MX340714B publication Critical patent/MX340714B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente solicitud proporciona los derivados de purina sustituidos y los compuestos relacionados de las fórmulas mostradas. Estos compuestos son útiles como inhibidores de HSP90, y por lo tanto, en el tratamiento de las enfermedades relacionadas. (Fórmulas) Z1-Z3, Xa-XC, X2, X4, Y y R son según lo definido en la especificación.
MX2012004089A 2009-10-07 2010-10-07 Inhibidores de hsp90. MX340714B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US24934909P 2009-10-07 2009-10-07
PCT/US2010/051872 WO2011044394A1 (en) 2009-10-07 2010-10-07 Purine derivatives useful as hsp90 inhibitors

Publications (2)

Publication Number Publication Date
MX2012004089A MX2012004089A (es) 2012-08-23
MX340714B true MX340714B (es) 2016-07-22

Family

ID=43857159

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2012004089A MX340714B (es) 2009-10-07 2010-10-07 Inhibidores de hsp90.

Country Status (16)

Country Link
US (2) US9328114B2 (es)
EP (2) EP2486039B1 (es)
JP (3) JP5941407B2 (es)
KR (2) KR101906568B1 (es)
CN (3) CN105924443A (es)
AU (1) AU2010303343B2 (es)
BR (1) BR112012008019A2 (es)
CA (1) CA2776308C (es)
DK (1) DK2486039T3 (es)
EA (1) EA029272B1 (es)
ES (2) ES2733131T3 (es)
LT (1) LT2486039T (es)
MX (1) MX340714B (es)
NZ (2) NZ625593A (es)
PT (1) PT2486039T (es)
WO (1) WO2011044394A1 (es)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9403828B2 (en) 2005-02-01 2016-08-02 Sloan-Kettering Institute For Cancer Research Small-molecule Hsp90 inhibitors
US7834181B2 (en) 2005-02-01 2010-11-16 Slaon-Kettering Institute For Cancer Research Small-molecule Hsp90 inhibitors
JP5599610B2 (ja) 2006-06-30 2014-10-01 スローン − ケッタリング インスティチュート フォー キャンサー リサーチ Ｈｓｐ９０の阻害による神経変性疾患の処置
AU2010303343B2 (en) 2009-10-07 2015-11-19 Sloan-Kettering Institute For Cancer Research Purine derivatives useful as HSP90 inhibitors
EP2694505B1 (en) 2011-04-05 2022-04-27 Sloan-kettering Institute For Cancer Research Hsp90 inhibitors
EA024647B1 (ru) 2011-04-05 2016-10-31 Слоун-Кеттеринг Инститьют Фо Кэнсэ Рисерч ИНГИБИТОРЫ Hsp90
CN109374889B (zh) 2011-07-08 2022-04-19 索隆-基特林癌症研究协会 标记的hsp90抑制剂的用途
US10201623B2 (en) 2013-03-15 2019-02-12 Memorial Sloan Kettering Cancer Center HSP90-targeted cardiac imaging and therapy
WO2015023976A2 (en) 2013-08-16 2015-02-19 Memorial Sloan-Kettering Cancer Center Selective grp94 inhibitors and uses thereof
NZ718190A (en) 2013-08-23 2017-10-27 Neupharma Inc Substituted quinazolines for inhibiting kinase activity
US9994573B2 (en) * 2013-12-23 2018-06-12 Memorial Sloan-Kettering Cancer Center Methods and reagents for radiolabeling
JP6835709B2 (ja) * 2014-09-17 2021-02-24 メモリアル スローン ケタリング キャンサー センター Ｈｓｐ９０を標的とした炎症及び感染のイメージング及び療法
EA201890623A1 (ru) 2015-10-05 2018-09-28 Мемориал Слоун Кеттеринг Кэнсер Сентр Рациональная комбинированная терапия для лечения рака
AU2017312561B2 (en) * 2016-08-15 2022-06-30 Neupharma, Inc. Certain chemical entities, compositions, and methods
AU2018257901A1 (en) * 2017-04-24 2019-11-14 Samus Therapeutics, Inc. Hsp90 inhibitor oral formulations and related methods
CN111683658A (zh) * 2017-06-23 2020-09-18 萨缪斯治疗股份有限公司 用于创伤性脑损伤及其后遗症的多蛋白复合物抑制剂疗法
WO2024229406A1 (en) 2023-05-04 2024-11-07 Revolution Medicines, Inc. Combination therapy for a ras related disease or disorder
US20250049810A1 (en) 2023-08-07 2025-02-13 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
TW202530228A (zh) 2023-10-12 2025-08-01 美商銳新醫藥公司 Ｒａｓ抑制劑
WO2025099111A1 (en) 2023-11-10 2025-05-15 Wella Germany Gmbh New telescoping syntheses of 6-hydroxy-benzomorpholine (3,4-dihydro-2h-1,4-benzoxazin-6-ol)
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
TW202547461A (zh) 2024-05-17 2025-12-16 美商銳新醫藥公司 Ｒａｓ抑制劑
WO2025255438A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2025265060A1 (en) 2024-06-21 2025-12-26 Revolution Medicines, Inc. Therapeutic compositions and methods for managing treatment-related effects
WO2026006747A1 (en) 2024-06-28 2026-01-02 Revolution Medicines, Inc. Ras inhibitors
WO2026015825A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Use of ras inhibitor for treating pancreatic cancer
WO2026015790A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015796A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015801A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026050446A1 (en) 2024-08-29 2026-03-05 Revolution Medicines, Inc. Ras inhibitors

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4903922B2 (ja) 1997-05-14 2012-03-28 スローン − ケッタリング インスティチュート フォー キャンサー リサーチ 選択された蛋白質を分解する複合化合物
WO2000061578A1 (en) 1999-04-09 2000-10-19 Sloan-Kettering Institute For Cancer Research Methods and compositions for degradation and/or inhibition of her-family tyrosine kinases
JP2005519848A (ja) 2000-11-02 2005-07-07 スローン−ケッタリング・インスティテュート・フォー・キャンサー・リサーチ Ｈｓｐ９０に結合するための小分子組成物
NL1019258C2 (nl) * 2001-10-30 2003-05-02 Iku Holding Montfoort Bv Bevestigingsconstructie, in het bijzonder voor een buitenspiegel van een motorvoertuig.
EP2336133A1 (en) 2001-10-30 2011-06-22 Conforma Therapeutics Corporation Purine analogs having HSP90-inhibiting activity
EP1450784A4 (en) 2001-11-09 2005-02-09 Conforma Therapeutics Corp HSP90-INHIBITABLE ZEARALANOL COMPOUNDS AND METHOD FOR THEIR PREPARATION AND USE
US7473699B2 (en) 2002-02-28 2009-01-06 Astrazeneca Ab 3-cyclyl-5-(nitrogen-containing 5-membered ring)methyl-oxazolidinone derivatives and their use as antibacterial agents
EP1620564A4 (en) 2003-04-18 2008-03-12 Cytovia Inc METHODS FOR TREATING DISEASES INDUCING APOPTOSIS INDUCTION AND SCREENING ASSAYS
EP2145888A1 (en) 2003-09-18 2010-01-20 Conforma Therapeutics Corporation Deazapurine derivatives as HSP90-Inhibitors
US7834181B2 (en) 2005-02-01 2010-11-16 Slaon-Kettering Institute For Cancer Research Small-molecule Hsp90 inhibitors
US9403828B2 (en) 2005-02-01 2016-08-02 Sloan-Kettering Institute For Cancer Research Small-molecule Hsp90 inhibitors
EP1913740A2 (en) 2005-07-27 2008-04-23 Qualcomm Incorporated System and method for a forward link only protocol suite
WO2007134298A2 (en) * 2006-05-12 2007-11-22 Myriad Genetics, Inc. Therapeutic compounds and their use in cancer
WO2007143629A1 (en) 2006-06-02 2007-12-13 Nexgenix Pharmaceuticals Treatment of neurofibromatosis with inhibitors of a signal transduction pathway
JP5599610B2 (ja) 2006-06-30 2014-10-01 スローン − ケッタリング インスティチュート フォー キャンサー リサーチ Ｈｓｐ９０の阻害による神経変性疾患の処置
US20080053862A1 (en) 2006-06-30 2008-03-06 Sanford, L.P. Interlocking Nestable Article Holder
CL2007002994A1 (es) * 2006-10-19 2008-02-08 Wyeth Corp Compuestos derivados heterociclicos que contienen sulfamoilo, inhibidores de hsp90; composicion farmaceutica; y uso para el tratamiento del cancer, tal como cancer de mama, de colon y prostata, entre otros.
US20080234297A1 (en) 2007-03-20 2008-09-25 Changgeng Qian HSP90 Inhibitors Containing a Zinc Binding Moiety
NZ579635A (en) * 2007-03-20 2011-07-29 Curis Inc Fused amino pyridine as hsp90 inhibitors
US20100240656A1 (en) * 2007-07-12 2010-09-23 Oryzon Genomics, S.A. Compounds as hsp90 inhibitors
WO2009042646A1 (en) 2007-09-24 2009-04-02 Curis, Inc. Anti-proliferative agents
CA2705579A1 (en) * 2007-11-14 2009-05-22 Myriad Pharmaceuticals, Inc. Therapeutic compounds and their use in treating diseases and disorders
AU2010303343B2 (en) 2009-10-07 2015-11-19 Sloan-Kettering Institute For Cancer Research Purine derivatives useful as HSP90 inhibitors
EA024647B1 (ru) 2011-04-05 2016-10-31 Слоун-Кеттеринг Инститьют Фо Кэнсэ Рисерч ИНГИБИТОРЫ Hsp90
EP2694505B1 (en) 2011-04-05 2022-04-27 Sloan-kettering Institute For Cancer Research Hsp90 inhibitors
WO2015023976A2 (en) 2013-08-16 2015-02-19 Memorial Sloan-Kettering Cancer Center Selective grp94 inhibitors and uses thereof

Also Published As

Publication number Publication date
CN105924443A (zh) 2016-09-07
EA201270535A1 (ru) 2012-09-28
US9328114B2 (en) 2016-05-03
US20160310497A1 (en) 2016-10-27
AU2010303343A1 (en) 2012-04-19
CN106083855B (zh) 2020-04-10
AU2010303343B2 (en) 2015-11-19
DK2486039T3 (en) 2016-09-12
CN102639534A (zh) 2012-08-15
EP3091019B1 (en) 2019-04-03
MX2012004089A (es) 2012-08-23
US10172863B2 (en) 2019-01-08
JP5941407B2 (ja) 2016-06-29
JP2013507381A (ja) 2013-03-04
CN106083855A (zh) 2016-11-09
EP2486039A1 (en) 2012-08-15
EP2486039A4 (en) 2012-08-15
KR20120083898A (ko) 2012-07-26
EP2486039B1 (en) 2016-06-01
KR101906568B1 (ko) 2018-10-10
BR112012008019A2 (pt) 2016-03-01
LT2486039T (lt) 2016-10-10
EA029272B1 (ru) 2018-03-30
PT2486039T (pt) 2016-09-06
JP6804483B2 (ja) 2020-12-23
WO2011044394A1 (en) 2011-04-14
CA2776308A1 (en) 2011-04-14
EP3091019A2 (en) 2016-11-09
JP2018104451A (ja) 2018-07-05
JP6326088B2 (ja) 2018-05-16
US20120208806A1 (en) 2012-08-16
ES2589403T3 (es) 2016-11-14
CA2776308C (en) 2020-01-28
NZ625593A (en) 2016-03-31
ES2733131T3 (es) 2019-11-27
NZ599138A (en) 2014-06-27
KR102129420B1 (ko) 2020-07-03
KR20180112117A (ko) 2018-10-11
EP3091019A3 (en) 2017-01-18
JP2016145262A (ja) 2016-08-12

Similar Documents

Publication Publication Date Title
MX340714B (es) Inhibidores de hsp90.
MY147994A (en) Azabiphenylaminobenzoic acid derivatives as dhodh inhibitors
PH12015501484A1 (en) Heteroaryl compounds and uses thereof
TW201129565A (en) Tricyclic heterocyclic compounds, compositions and methods of use thereof
MX2013004491A (es) Boronatos como inhibidores de arginasa.
MX2010001754A (es) Derivados de azepina como inhibidores de gamma secretasa.
NO20083427L (no) Cystoksiske midler omfattende nye tomaymycinderivater og deres terapeutiske anvendelse
MX353308B (es) Derivados fosforosos como inhibidores de cinasa.
MX338327B (es) Inhibidores de cdk.
MX2009009590A (es) Aminopirimidinas utiles como inhibidores de proteinas cinasas.
EA201100580A1 (ru) Имидазопиридазинкарбонитрилы, используемые в качестве ингибиторов киназы
MX2009010595A (es) Derivados de pirrolopirimidina.
MY163477A (en) Pyrimidinyl-pyridazinone derivatives
MX2010003366A (es) Derivados de piperidina y piperazina para el tratamiento de tumores.
WO2010003475A3 (de) Neue pyrrolidinderivate als metap-2 inhibitoren
MX2009013077A (es) Derivados dde benzoxazolona.
EA201170521A1 (ru) Новые соединения
NZ589844A (en) Thiophene or thiazole derivatives and their use as phosphatidylinositol 3-kinase (PI3K) inhibitors
UA100540C2 (en) 2-benzylpyridazinone derivatives as met kinase inhibitors
EA200801428A1 (ru) Производные пиридиазинона для лечения опухолей
EA024194B8 (ru) Содержащие диарилацетиленгидразид ингибиторы тирозинкиназы
MX2012002876A (es) Derivados de dihidropteridinona, proceso para su preparacion y uso farmaceutico.
IN2012DN03182A (es)
WO2009132774A8 (en) New substituted indolin-2-one derivatives and their use as p38 mitogen-activated kinase inhibitors
MX2014003376A (es) Derivados de acido benzoico como inhibidores eif4e.

Legal Events

Date Code Title Description
FG Grant or registration